AAV Vector Segmentation for Large Microdystrophin Packaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy vectors, such as Adeno-Associated Virus (AAV), face limitations in packaging DNA sequences larger than 5 kb, which is a challenge for effectively treating Duchenne and Becker muscular dystrophies due to the size constraints of the dystrophin gene, leading to truncated genomes and lower expression efficiency.
Innovation Solution
The development of AAV vectors that can package oversized DNA sequences encoding larger active microdystrophins, including those with extended central rod and C-terminal domains, allowing for the production of functional dystrophin proteins that exceed the traditional size limits, thereby addressing the packaging limitations and enhancing therapeutic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV vectors are used to deliver dystrophin gene therapy, then long-term gene transduction in muscle cells is achieved, but the cargo capacity limitation of around 5 kb prevents packaging of the full-length dystrophin gene
Solution Approach 1:
The dystrophin gene is divided into two separate expression cassettes: one encoding the N-terminal domain (exons 1-62) and another encoding the C-terminal domain (exons 63-79). Each cassette is packaged into a separate AAV vector, allowing both large functional domains to be delivered within the 5 kb cargo capacity limit while achieving long-term transduction in muscle cells.
2Adaptability or versatility
If oversized DNA sequences are packaged in AAV vectors, then larger microdystrophins encompassing rod and CT domains can be produced, but truncated packaged genomes and heterogeneous population result
Solution Approach 1:
The oversized DNA sequence encoding microdystrophin with both rod and CT domains is segmented into two manageable cassettes that fit within AAV cargo capacity. This segmentation prevents genome truncation and heterogeneity while enabling production of larger, more functional microdystrophin variants that include previously excluded domains.
3Reliability
If the full-length dystrophin gene is targeted for therapy, then complete functional restoration is achieved, but the gene size of 2.5 Mb exceeds all current gene therapy vector systems
Solution Approach 1:
The 2.5 Mb dystrophin gene is segmented into two strategic portions: the N-terminal cassette (exons 1-62) and C-terminal cassette (exons 63-79). Each cassette is packaged in a separate AAV vector, enabling delivery of the complete functional gene within the constraints of current vector systems while achieving reliable functional restoration in dystrophic muscle tissue.
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
An adeno-associated viral (AAV) vector containing an expression construct, wherein: - the expression construct comprises a nucleic acid sequence which encodes a microdystrophin (MD); and - the nucleic acid sequence encoding the MD has a size of at least 4,1 kb.